How the Amylin Pathway Works
Amylin is a fullness hormone released by the pancreas at mealtimes — separate from GLP-1, working via different brain regions. Because it hits different receptors, combining it with GLP-1 produces additive appetite suppression rather than simple overlap.
Quick read · 4 min
Two separate brain pathways — additive effects
What amylin is
Amylin (also called IAPP — islet amyloid polypeptide) is a hormone co-secreted with insulin by the beta cells of the pancreas — specifically at mealtimes. Its primary job is to signal satiety and slow the speed at which food leaves the stomach.
People with type 2 diabetes have impaired amylin secretion alongside impaired insulin secretion. This partly explains why they often experience dysregulated satiety.
How amylin suppresses appetite
Amylin works via distinct brain regions and pathways to GLP-1:
- Area postrema accessAmylin acts on the area postrema in the brainstem — a brain region without a blood-brain barrier, meaning hormones can directly access it. This signal is relayed to the lateral hypothalamus to suppress appetite.
- Reward circuit suppressionAmylin modulates the ventral tegmental area and medial prefrontal cortex — suppressing impulsive food-seeking behaviour and reducing the reward value of food.
- Gastric slowingLike GLP-1, amylin slows gastric emptying — food stays in the stomach longer, prolonging the feeling of fullness.
- Glucagon suppressionAmylin suppresses glucagon secretion after meals, contributing to blood sugar control.
Why combining with GLP-1 matters
Plain English:
Amylin is a separate fullness signal — released by the pancreas at mealtimes, it tells the brain you've eaten enough through different nerve pathways to GLP-1. Combining amylin signals with GLP-1 signals appears to produce additive weight loss, because each signal reinforces the other from different angles in the brain.
GLP-1 and amylin act on different receptors in different brain regions. Their effects do not overlap significantly — they are complementary. In Phase 3 trials, CagriSema (cagrilintide + semaglutide) produced 20.4% mean weight loss — notably greater than semaglutide alone (~15%) in comparable populations.
Pipeline status
Neither CagriSema nor Amycretin is currently approved. CagriSema has had an NDA filed with the FDA (December 2025) and is under review. Amycretin is in earlier development (Phase 3 planned). These drugs are not available for prescription.
Common questions
Next step most people take
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: April 2026